Who We Are
Oyster Point is a clinical stage pharmaceutical company leveraging neuroscience to discover, develop and commercialize novel therapies to treat diseases with high unmet needs, beginning with ophthalmic diseases.
The two lead compounds are highly selective nAChR agonists intended to stimulate the Trigeminal Parasympathetic Pathway (TPP). Both are in Phase 2 clinical development for signs and symptoms of Dry Eye Disease.
Stay up to date on our latest news – Oyster Point Raises $93 Million to Support the Clinical Development of Novel Treatment for Dry Eye Disease.